HC Wainwright Reaffirms Buy Rating for Aligos Therapeutics (NASDAQ:ALGS)

HC Wainwright reiterated their buy rating on shares of Aligos Therapeutics (NASDAQ:ALGS) in a research note published on Friday morning, Benzinga reports. The brokerage currently has a $75.00 price target on the stock.

Aligos Therapeutics Stock Performance

Shares of ALGS opened at $8.10 on Friday. The firm has a market cap of $632.69 million, a P/E ratio of -6.33 and a beta of 2.18. Aligos Therapeutics has a 52 week low of $7.80 and a 52 week high of $30.00. The firm’s 50-day simple moving average is $13.09 and its 200 day simple moving average is $16.08.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of ($4.00) by $4.75. The business had revenue of $1.06 million for the quarter. Aligos Therapeutics had a negative net margin of 1,100.48% and a negative return on equity of 110.59%. During the same period in the prior year, the business posted ($10.75) earnings per share. As a group, equities analysts forecast that Aligos Therapeutics will post -8.15 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Armistice Capital LLC raised its stake in shares of Aligos Therapeutics by 5.3% during the second quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock valued at $2,540,000 after acquiring an additional 363,000 shares during the last quarter. Altitude Crest Partners Inc. acquired a new stake in Aligos Therapeutics during the 4th quarter valued at approximately $1,889,000. Opaleye Management Inc. raised its holdings in Aligos Therapeutics by 25.7% during the 1st quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after purchasing an additional 333,000 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its position in shares of Aligos Therapeutics by 26.1% in the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock worth $289,000 after purchasing an additional 171,490 shares during the period. Institutional investors and hedge funds own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).